3-(4-氯苯基)-1-甲基-1H-吡唑-5-胺 | 126417-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(4-氯苯基)-1-甲基-1H-吡唑-5-胺
• 英文名称: 3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-ylamine
• 英文别名: 3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-amine；5-Amino-3-(p-chlorphenyl)-1-methyl-pyrazol；5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-ylamine；5-amino-3-(4-chlorophenyl)-1-methylpyrazole；5-(4-chlorophenyl)-2-methylpyrazol-3-amine
• CAS: 126417-82-1
• 化学式: C₁₀H₁₀ClN₃
• 分子量: 207.662
• InChiKey: ZSFCXTGPGSAWFT-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090

SDS

Name:	3-(4-Chlorophenyl)-1-methyl-1h-pyrazol-5-amine Material Safety Data Sheet
Synonym:
CAS:	126417-82-1

Section 1 - Chemical Product MSDS Name:3-(4-Chlorophenyl)-1-methyl-1h-pyrazol-5-amine Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
126417-82-1	3-(4-Chlorophenyl)-1-methyl-1h-pyrazol	97+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. Causes gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 126417-82-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Grey
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 170 - 172 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10CLN3
Molecular Weight: 207.66

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 126417-82-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(4-Chlorophenyl)-1-methyl-1h-pyrazol-5-amine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
WGK (Water Danger/Protection)
CAS# 126417-82-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 126417-82-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 126417-82-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯基)-1-甲基-1H-吡唑-5-胺 在 三氯氧磷 作用下， 生成 4-Chloro-3-(4-chloro-phenyl)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester
  参考文献：
  名称：

  Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors

  摘要：

  合成了一系列4-氨基吡唑并吡啶衍生物，并对其作为磷酸二酯酶（PDE4）抑制剂进行生物评估。对3这一我们内部库中发现的结构新颖的化学先导物的化学改造主要集中在1-和3-取代基上。本文详细介绍了新型口服活性化学先导物5的发现，以及结构-活性关系数据、药理评估和亚型选择性研究的结果。

  DOI：

  10.1248/cpb.52.1098
• 作为产物：
  描述：

  4-氯苯甲酸乙酯 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 、 水 、 mineral oil 为溶剂， 反应 9.0h， 生成 3-(4-氯苯基)-1-甲基-1H-吡唑-5-胺
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Pyrazolo[3,4-<i>b</i>]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors

  摘要：

  设计、合成并评估了一系列1,3,6-三苯基吡唑并[3,4-b]吡啶-4-酮衍生物在A375人黑素瘤细胞和人类红细胞白血病（HEL）细胞中的细胞毒性活性。这些新的吡唑吡啶酮表现出与抗肿瘤化合物依托泊苷相当的活性。化合物17、18、27和32对拓扑异构酶II介导的裂解活性的抑制效果进行了测量，发现与MTS测定结果有良好的相关性。同时，对细菌拓扑异构酶II（DNA旋转酶）、拓扑异构酶IIα和拓扑异构酶IIβ在DNA结合界面上的结合位点进行了对接研究。

  DOI：

  10.2174/1573406411666141210141317
• 作为试剂：
  描述：

  3-甲基-4-羟基苯甲醛 在 2-溴-2-甲基丙酸乙酯 、 3-(4-氯苯基)-1-甲基-1H-吡唑-5-胺 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 2-(4-{[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-ylimino]-methyl}-2-METHYL-PHENOXY)-2-METHYL-PROPIONIC acid ethyl ester
  参考文献：
  名称：

  [EN] PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS
  [FR] COMPOSES CHIMIQUES

  摘要：

  公开号：

  WO2004000785A3

文献信息

• [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078408A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078331A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
• [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078454A1

  公开（公告）日：2014-05-22

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式I的化合物：或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C和X如本文定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
• Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors
  作者：Gustav Boije af Gennäs、Luca Mologni、Shaheen Ahmed、Mohanathas Rajaratnam、Oriano Marin、Niko Lindholm、Michela Viltadi、Carlo Gambacorti-Passerini、Leonardo Scapozza、Jari Yli-Kauhaluoma

  DOI：10.1002/cmdc.201100168

  日期：2011.9.5

  on the development of inhibitors for targeted therapy of these ALK‐positive tumors. Because kinase inhibitors that target the inactive conformation are thought to be more specific than ATP‐targeted inhibitors, we investigated the possibility of using two known inhibitors, doramapimod and sorafenib, which target inactive kinases, to design new urea derivatives as ALK inhibitors. We generated a homology

  在间变性大细胞淋巴瘤中，涉及间变性淋巴瘤激酶（ALK）激酶结构域的染色体易位通常与核磷蛋白基因的5'部分融合，会产生高度致癌的ALK融合蛋白，从而破坏这些细胞的细胞周期，凋亡和分化。细胞。最近在患有非小细胞肺癌，乳腺癌和结直肠癌的患者中发现了其他涉及ALK的融合癌蛋白，例如棘皮动物微管相关蛋白4-ALK。最近的研究集中在针对这些ALK阳性肿瘤的靶向治疗的抑制剂的开发上。由于靶向无活性构象的激酶抑制剂被认为比针对ATP的抑制剂更具特异性，因此我们研究了使用两种已知的靶向无活性激酶的抑制剂doramapimod和sorafenib的可能性，设计新的尿素衍生物作为ALK抑制剂。我们在其活性位点与多拉吡莫德或索拉非尼复合的非活性构象中生成了ALK的同源模型。结果阐明了为什么doramapimod是一种弱抑制剂，为什么sorafenib不抑制ALK。使用ALK的同源性模型对市售化合物进行的虚拟筛选产
• [EN] ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES<br/>[FR] DERIVES D'ANILINO-PYRAZOLE UTILISES DANS LE TRAITEMENT DES DIABETES
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2004050650A1

  公开（公告）日：2004-06-17

  The present invention relates to anilinopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.

  本发明涉及苯基氨嘧唑化合物、药物组合物以及用于治疗糖尿病和相关紊乱的方法。